Today, we shared some big news! Medtronic announced its intent to separate our Diabetes business into a standalone, public company. This next chapter enables us to relentlessly focus and accelerate strategic investments in areas that will most benefit you — from breakthrough innovations, five-star customer experience to scaling automated manufacturing to meet growing demand for our technologies. We’re unique in Medtronic as a direct-to-consumer business so this is a win-win as it allows both companies to strategically focus on our core strengths.

I wanted to personally reach out regarding the recent approval of our Simplera Sync™ sensor. While this should have been a moment of celebration, I understand many of you were disappointed by our communication. Over the past few days, I’ve had the privilege of speaking with many of you and listening to your concerns.

Medtronic access programs that may help reduce the cost of insulin pumps, CGMs, smart insulin pens, and ongoing supplies.

Understand the concept of active insulin and how the Bolus Wizard™ feature factors in active insulin time.

Hear from avid cyclist and Medtronic employee, Heidi, on her experience training for long-distance cycling with type 1 diabetes.